What Is Apimostinel? Definition and What Research Reports

Definition

Apimostinel (also referred to by the development code NRX-1074) is an investigational, peptide-derived compound that the published literature groups into a family of molecules called stinels, described as positive allosteric modulators of the N-methyl-D-aspartate (NMDA) glutamate receptor rather than channel-blocking antagonists such as ketamine (PMID 40005971). It is described in reviews of glutamatergic antidepressant candidates as a structural analogue of rapastinel, and it has been catalogued alongside other experimental agents in surveys of the rapid-acting antidepressant pipeline (PMID 33904154, PMID 30447328). Apimostinel is not an approved medicine in the United States or elsewhere, and this glossary entry defines the term only; it does not describe use.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, symptoms, or treatment.

What class of molecule is it?

The term sits at the boundary between peptide chemistry and small-molecule pharmacology, which is why it appears in peptide glossaries at all. Stinels are described in the literature as peptide and peptide-derived neuroplastogens whose defining feature is allosteric modulation of the NMDA receptor, a mechanism distinct from the open-channel blockade produced by ketamine and related agents (PMID 40005971). Apimostinel is discussed in that context as a later-generation analogue in the same chemical series as rapastinel (PMID 33904154).

Broader pharmacology reviews place the compound within a much larger effort to target glutamatergic neurotransmission — NMDA receptors, AMPA receptors, and the GABA–glutamate balance — as an alternative to monoamine-based antidepressant mechanisms (PMID 40840695, PMID 38004437). Reviews of small molecules acting at NMDA receptors similarly treat allosteric modulators as a separate design strategy from competitive antagonists and channel blockers (PMID 41188625).

Naming conventions

• Apimostinel — the international non-proprietary style name; the -stinel stem is used in the literature for this receptor-modulator class (PMID 40005971).
• NRX-1074 — the development code that appears in older pipeline reviews of novel and rapid-acting antidepressant candidates (PMID 30447328).
• Rapastinel (GLYX-13) — the earlier compound in the same series against which apimostinel is usually described in reviews (PMID 33904154).

Where the term comes from

Apimostinel entered the vocabulary of psychiatric pharmacology through the drug-development literature rather than through classical peptide endocrinology. Reviews tracing the emergence of new antidepressants listed it among pipeline agents being examined at a time when interest in glutamate-targeting mechanisms was expanding rapidly (PMID 31211282). A 2019 review of the pharmaceutical pipeline for rapid-acting therapeutics in mood disorders grouped such candidates by their glutamate and GABA mechanisms, which is the framework in which the name is normally encountered (PMID 30447328).

How the term is used in peptide research

In practice, writers use "apimostinel" in three ways:

1. As a class example. It is cited as a representative stinel when authors contrast allosteric NMDA modulation with channel blockade (PMID 40005971).
2. As a pipeline marker. It appears in tables of investigational glutamatergic modulators that map what has been studied for mood disorders (PMID 33904154).
3. As a mechanistic reference point. It is invoked in discussions of whether synaptic plasticity and downstream AMPA-receptor signalling can be engaged without producing the dissociative profile associated with NMDA antagonists (PMID 40840695).

Related terms readers often encounter alongside it

What the published literature reports

The available secondary literature is mechanistic and pipeline-oriented rather than definitive. Researchers writing a 2025 analysis of the stinel class reported that these compounds act as positive allosteric modulators at the NMDA receptor and framed them as neuroplastogens, proposing that this mechanism — not receptor blockade — underlies the antidepressant effects studied in the class (PMID 40005971). A 2021 review of novel glutamatergic modulators surveyed the current status of agents including stinel-class compounds and reported that the field remained in active investigation rather than settled (PMID 33904154).

Wider reviews place that work in context. A 2025 review of glutamate-system targets reported that both NMDA and AMPA receptors have been pursued as entry points for rapid-acting antidepressant effects (PMID 40840695), and a 2023 review of GABA–glutamate pharmacotherapies for treatment-resistant depression catalogued the agents that had been examined in that space (PMID 38004437). A 2026 review of small molecules targeting NMDA receptors reported continued medicinal-chemistry work on modulators of this receptor family (PMID 41188625). No dose, schedule, or route is described on this page, because the verified sources cited here are reviews of mechanism and pipeline status rather than protocol reports.

Tolerability: What Studies Report

Discussions of the stinel class have emphasised the pharmacological rationale for allosteric modulation over channel blockade, with the 2025 class analysis reporting that positive allosteric modulation of the NMDA receptor is mechanistically distinct from the blockade produced by dissociative NMDA antagonists (PMID 40005971). Review authors surveying novel glutamatergic modulators reported that tolerability considerations — particularly psychotomimetic and dissociative effects seen with NMDA antagonists — have shaped which mechanisms were carried forward in development (PMID 33904154). Pipeline reviews of new antidepressants similarly reported that candidate agents in this space have had mixed trajectories through clinical development (PMID 31211282). No compound-specific adverse-event rates for apimostinel are stated here, as none appear in the verified sources.

Regulatory status

Apimostinel is not an approved drug product. It is referred to in the literature as an investigational agent within pipeline reviews of novel and rapid-acting antidepressant candidates (PMID 30447328). Material bearing this name outside of a sanctioned clinical trial or licensed manufacturing setting would generally fall under research-use-only labelling, which is not a marketing authorisation and carries no claim of safety or efficacy in humans.

One-line summary

Apimostinel (NRX-1074): investigational peptide-derived stinel; positive allosteric modulator of the NMDA receptor; analogue of rapastinel; studied in the context of glutamate-targeting, rapid-acting antidepressant research (PMID 40005971, PMID 33904154).

References

• Demystifying the Antidepressant Mechanism of Action of Stinels, a Novel Class of Neuroplastogens: Positive Allosteric Modulators of the NMDA Receptor (Pharmaceuticals, 2025)
• Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status (CNS Drugs, 2021)
• All roads lead to glutamate: NMDA and AMPA receptors as targets for rapid-acting antidepressants (Pharmacological Research, 2025)
• Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (Pharmaceuticals, 2023)
• New advances in small molecule drugs targeting NMDA receptors (Acta Pharmacologica Sinica, 2026)
• A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems (Drug Discovery Today, 2019)
• The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents (IBRO Reports, 2019)